Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.

Antimicrobial agents and chemotherapy, Volume: 67, Issue: 11
November 15, 2023
Michelle E Ramey ME, Firat Kaya F, Allison A Bauman AA, Lisa M Massoudi LM, Jansy P Sarathy JP, Matthew D Zimmerman MD, Dashick W L Scott DWL, Alyx M Job AM, Jake A Miller-Dawson JA, Brendan K Podell BK, Michael A Lyons MA, VĂ©ronique Dartois V, Anne J Lenaerts AJ, Gregory T Robertson GT

BTZ-043, a suicide inhibitor of the cell wall synthesis decaprenylphosphoryl-beta-D-ribose 2′ epimerase, is under clinical development as a potential new anti-tuberculosis agent. BTZ-043 is potent and bactericidal but has limited activity against non-growing bacilli in rabbit caseum. To better understand its behavior , BTZ-043 was evaluated for efficacy and spatial drug distribution as a single agent in the C3HeB/FeJ mouse model presenting with caseous necrotic pulmonary lesions upon infection. BTZ-043 promoted significant reductions in lung and spleen bacterial burdens in the C3HeB/FeJ mouse model after 2 months of therapy. BTZ-043 penetrates cellular and necrotic lesions and was retained at levels above the serum-shifted minimal inhibitory concentration in caseum. The calculated rate of kill was found to be highest and dose-dependent during the second month of treatment. BTZ-043 treatment was associated with improved histology scores of pulmonary lesions, especially compared to control mice, which experienced advanced fulminant neutrophilic alveolitis in the absence of treatment. These positive treatment responses to BTZ-043 monotherapy in a mouse model of advanced pulmonary disease can be attributed to favorable distribution in tissues and lesions, retention in the caseum, and its high potency and bactericidal nature at drug concentrations achieved in necrotic lesions.

Courtesy of the U.S. National Library of Medicine